The U.S. Department of the Treasury and the Internal Revenue Service are preparing to issue new tax guidance following the Department of Justice’s final order to reclassify certain medical marijuana products from Schedule I to Schedule III under the Controlled Substances Act. This shift, driven by President Donald Trump’s December 2025 executive order, is poised to deliver significant tax relief to state-licensed medical marijuana businesses by lifting the punitive constraints of Section 280E.
Section 280E of the Internal Revenue Code has long barred businesses dealing in Schedule I or II substances from claiming standard deductions and credits, forcing cannabis operators to shoulder higher effective tax rates by disallowing write-offs for expenses like payroll and rent. With the DOJ’s action placing FDA-approved marijuana products and state-licensed medical marijuana into Schedule III, qualifying businesses are expected to escape these restrictions, potentially transforming their financial outlook.
Treasury officials noted that the rescheduling will generally apply to the full taxable year including the effective date of the DOJ’s final order for activities no longer tied to Schedule I or II substances. This transition rule aims to provide immediate clarity for medical marijuana operators planning their 2026 filings.
READ: US Plans Retroactive 280E Tax Break For Operators Per Marijuana Reclassification, But Not For All
However, a notable distinction has emerged regarding the scope of relief. The DOJ administrator has urged the Treasury to consider retrospective relief from Section 280E liability for prior taxable years in which state licensees operated under medical marijuana licenses, a move that could allow qualifying operators to reclaim past overpayments or amend returns.
Here’s the text included within today’s Department of Justice Final Order:
“The Administrator encourages the Secretary of the Treasury to consider providing retrospective relief from Section 280E liability for taxable years in which a state licensee operated under a state medical marijuana license.”
And here’s the text within the Department of the Treasury’s press release:
“Guidance is also expected to include a transition rule providing that, for purposes of section 280E, rescheduling generally will be considered to first apply for a business’s full taxable year that includes the effective date of the Final Order, for the business’s activities that do not involve Schedule I or II controlled substances as a result of the Final Order.”
The Treasury has yet to confirm whether it will adopt the recommendation from the DOJ, or instead proceed with changes just applying to the current taxable year, creating uncertainty over the full extent of potential benefits.
The guidance will also tackle complexities for businesses with mixed operations. Companies juggling Schedule III medical marijuana activities alongside Schedule I or II substances—such as unlicensed crops or bulk marijuana—can expect rules on expense apportionment to clarify how deductions apply across their revenue streams.
READ: US Justice Department Reclassifies Marijuana to Schedule III in Historic Drug Policy Shift
A critical limitation shapes the impact of this policy shift. The tax relief targets only medical marijuana operators, leaving the broader adult-use cannabis sector under the existing federal constraints of Section 280E. For multi-state operators, the split between medical and recreational revenue could now dictate their tax burden more than ever.
The divide underscores a fragmented landscape for the cannabis industry in 2026. While medical operators may gain a competitive edge with lower tax pressures, adult-use businesses remain sidelined, facing effective tax rates that can exceed 70% in some cases due to disallowed deductions.
Information for this story was found via the sources and companies mentioned. The author has no securities or affiliations related to the organizations discussed. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.
